The Weill Cornell Brain and Spine Center is a national leader in clinical trials and research studies for neurosurgical conditions. These initiatives help achieve our mission of bringing our patients groundbreaking approaches to improving their diagnosis and treatment.
Note: Clinical Trials (listed below) enroll patients in controlled tests of treatment options. Research Studies collect data about patients, treatments, and outcomes to help guide future treatment decisions. (See list of Research Studies)
Clinical trials are currently enrolling for:
Brain Tumors | Cerebrovascular Disorders | Epilepsy
Pediatric Neurosurgery | Movement Disorders
Pseudotumor Cerebri | Spine Conditions
Or review the complete list of our exciting clinical trials and studies (below).
This is a multicenter, randomized, open-label study of Toca 511 and Toca FC versus standard of care (SOC) in subjects undergoing resection for first or second recurrence (including this recurrence) of glioblastoma or anaplastic astrocytoma. Subjects will be randomized at the time of surgery in a 1:1 ratio to receive either Toca 511 and Toca FC or control; Investigator's choice of either single agent chemotherapy (lomustine or temozolomide) or bevacizumab.
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)
This study tests an innovative convection-enhanced delivery (CED) technique that places a radioactive therapeutic agent (124I-8H9) at the site of the tumor using a surgically placed cannula.
The Cordis ENTERPRISE Vascular Reconstruction Device and Delivery System is authorized by federal law as a Humanitarian Use Device (a designation for devices that will be used to treat fewer than 4,000 people a year) for use with embolic coils for the treatment of wide-necked, intracranial aneurysms.
Addictive disorders are prevalent ailments that incur very high personal and social costs. In particular, cocaine addiction results in significant and permanent systemic changes to a patient, in addition to reducing personal and social productivity. While current therapies for cocaine addiction include psychosocial community reinforcement approaches, "vouchers" for abstinence, individual counseling, and pharmacologic treatment, there is a need for new tools for patients who relapse despite these conventional methods.
The purpose of this study is to develop a technique for the intraoperative identification of human functional and epileptiform cortex using intrinsic signal imaging
Medtronic Deep Brain Stimulation (DBS) Therapy for Dystonia is used to manage the symptoms of dystonia. It has been designated a Humanitarian Use Device (HUD) by the FDA and has been approved by the FDA under the Humanitarian Device Exemption (HDE) to aid in the management of certain types of chronic, intractable (drug refractory) dystonia. Brain stimulation involves the use of an implanted lead or leads to deliver electrical stimulation to parts of the brain to help control movement. Stimulation of these areas enables the brain circuits that control movement to function better.
The LVIS HUD is a stent (a small metallic mesh tube) that will be placed across the neck of the aneurysm; it is intended to remodel the blood vessel as well as provide support for the coils that will be placed inside the aneurysm. The purpose of the coils is to facilitate aneurysm occlusion by blocking blood flow into the aneurysm. The purpose of the treatment is to close off the aneurysm neck and lower the chance of aneurysm rupture.
It is unknown if currently used intravenous (IV) therapies even cross the blood brain barrier (BBB). We have shown in previous phase I trials that a single Superselective Intra-arterial Cerebral Infusion (SIACI) of Cetuximab and/or Bevacizumab is safe for the treatment of recurrent glioblastoma multiforme (GBM) in adults, and we are currently evaluating the efficacy of this treatment.
To provide deep brain stimulation therapy to alter pathological functioning of circuitry involved in causing medically-resistant obsessive-compulsive disorder.
Overview: MPS IIIA is predominantly a central nervous system disease causing cognitive disability, progressive loss of acquired skills, behavioral and sleep disturbance. LYS-SAF302 is a gene therapy which is intended to deliver a functional copy of the SGSH gene to the brain. This is a phase 2-3 study to assess the efficacy in improving or stabilizing the neurodevelopmental state of MPS IIIA patients.
This study has been designed as a single-blinded, multi-center, randomized clinical trial at New York Presbyterian Hospital Columbia and New York Presbyterian Hospital Cornell. The study population includes all adult craniotomies performed at each institution over a 4 year and 9 month time period. The treatment variable is the application of topical vancomycin to the surgical site. If a craniotomy is performed, a paste made from vancomycin powder and sterile solution will be applied to the edges and outer surface of the craniotomy.
There are many patients with Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri, who do not respond to available treatments or experience medication-related side effects that affect their quality of life. A new clinical trial aims to evaluate the safety and efficacy of venous sinus stenting in patients with refractory IIH and significant venous sinus stenosis.
The Wingspan Stent System with the gateway tm PTA balloon catheter is intended for use in improving cerebral artery lumen diameter in patients with intracranial atherosclerotic disease refractory to medical therapy, in intracranial arteries with greater than or equal to 50% stenosis.
